亚洲欧美精品在线-亚洲欧美精品中文字幕在线观看-亚洲欧美精品综合在线观看-亚洲欧美精选-亚洲欧美久久-亚洲欧美久久精品

Hello! Welcome to the official website of Betta Pharmaceuticals!
Service Hotline:+86-571-86130357     Add to Favorites | Online Feedback 中文


Icotinib hydrochloride is a National Class 1.1 new drug that is independently developed by Betta Pharmaceuticals Co., Ltd. for nearly a decade. It is also China's first small molecule targeted anti-cancer drug. Icotinib is a potent and highly selective oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), and it is used for the first-line treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) patients carrying EGFR mutations. 
On June 7th, 2011, Icotinib hydrochloride was approved by the National Medical Products Association (NMPA), fulfilling the unmet medical needs in China.
On August 12th, 2011, the market launch of Icotinib hydrochloride was held in the Great Hall of the People in Beijing. It was praised as a groundbreaking scientific and technological achievement in the China healthcare industry.
In 2012, Icotinib hydrochloride was included on Citeline’s “Pharm R&D Annual Review for 2012”, which was the first time a Chinese innovative drug was included on such report.
On August 13th, 2013, the phase III ICOGEN clinical trial results of Icotinib hydrochloride were published on the Lancet Oncology (Shi, Y., et al., The Lancet Oncology 14 (10) p953-961). Professor of the University of Colorado, Dr. David Camidge, commented that Icotinib has opened a new era of anticancer drug research in China, which is a significant milestone in the global oncology research.

1698306007803090.png

In 2012 and 2014, icotinib hydrochloride won the Golden Prize of Chinese Patent Award for its composition of matter and the crystal form patents.
In 2015, icotinib hydrochloride won “First Prize of National Science and Technology Progress Award 2015”.
In 2016, icotinib hydrochloride won “Chinese Industry Award”. In the same year, it was included in the first round of the price negotiation with the Chinese National Health Commission and created a new model for medical insurance negotiation, which reduced the burden of Chinese patients.
In 2017, icotinib hydrochloride was enlisted on the National Reimbursement Drug List (NRDL). On July 19th, the BRAIN clinical study results of icotinib hydrochloride for NSCLC brain metastasis treatment were published in the Lancet Oncology (Jin-Ji, Y., et al., The Lancet Oncology 5 (9) p707-716). It is the first phase III study of EGFR TKI targeting NSCLC patients with brain metastasis, and this treatment is recommended in the clinical guide. On August 23rd, the first-line clinical study of icotinib hydrochloride in NSCLC patients carrying EGFR mutations was published in the Annual of Oncology, which provided clinical support for its use in the first-line setting.
In 2018, icotinib hydrochloride was included on the National Essential Drug List (EDL), giving access to more Chinese patients.
In 2019, icotinib hydrochloride was included on the General Drug Access Catalogue of National Medical Insurance, further reducing the economic burden of NSCLC patients.



1.png

主站蜘蛛池模板: 精品人妻无码一区二区色欲产成 | 免费无码又爽又黄又刺激网站 | 亚洲AV无码一区二区A片成人 | 1区2区3区4区产品乱码90免费播放 | 国产不卡视频在线观看 | 欧美熟妇另类久久久久久多毛 | 精品视频福利 | 爱v在线一区二区国产精品 爱爱帝国亚洲一区二区三区 | 国产午夜精品一区二区三区软件图片在线电视野花日本大全 | 国色天香网| 国产精品亚洲日韩欧美色窝窝 | 理论亚洲区美一区二区三区 | 麻豆91传媒一区二区三 | 人妻aⅴ中文字幕无码 | 国产一级一国产一级毛片 | 久久无码av一区二区三区成人黑人美女毛片人妻 | 2024国产午夜福利久久 | 色天使久久综合给合久久色 | 欧美人成在线观看 | 成人久久国产字幕一区二区三区 | 日韩精品一区二区av片在线观看 | 精品日产1区2卡三卡麻豆全集精选 | 国产中文字幕在线免费观 | 羞羞影院午夜男女爽爽影院网站 | 2024国产精品视频 | 制服亚洲另类 | 日韩精品不卡一区二区 | 色精品视频在线观看免费 | 精品久久久国产中文字幕 | 噜噜综合亚洲av中文无码 | 久久侵犯人妻中文字幕 | 国产福利视频在线精品 | 欧美日韩国产在线人成网站欧美日韩国产综合 | 丁香五月天在线国产亚洲 | 国产精品亚洲专区 | 欧美综合自拍视频网站 | w色综合久久精品中文字幕 | 成人福利| 国模粉嫩小泬视频在线观看 | 国产亚洲日韩网曝欧 | 五月色丁香综合成人网 |